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Background:  We  investigated  myocardial  protection  by  human  atrial  natriuretic  peptide  (hANP)  dur-
ing  cardiac  surgery  without  cardioplegia  and  determined  whether  suppression  of  myocardial  ischemic
reperfusion  injury  by hANP  allows  intraoperative  aortic  cross-clamp  time  to be prolonged.
Methods  and results:  Thirty-two  pigs  were  placed  on cardiopulmonary  bypass.  Experimental  pigs were
divided  into  4  groups:  15 min  clamping;  hANP  15  min  clamping;  30  min  clamping;  and  hANP  30  min
clamping.  In both  hANP  groups,  a 100  g dose  of  hANP  was  administered  after  clamping.  Left  ventricular
function,  premature  ventricular  contractions  (PVCs),  histopathological  studies,  8-isoprostane,  myocardial
Ca2+,  and  ATP  concentrations  were  determined.  Comparison  of  the  myocardial  contractile  force  indicator
Emax,  in the 30  min  groups,  showed  a signiﬁcantly  higher  recovery  rate in  the  hANP  than  in the  control
group.  PVC  numbers  were  signiﬁcantly  lower  in the  hANP  than  in  the  control  groups  for  both  arrest
durations.  On microscopic  examination,  hANP  reduced  ischemic  reperfusion  injury  in the  30  min  groups.
The myocardial  ATP  level  was  signiﬁcantly  higher  in  the hANP  30  min  than  in the  control  30 min  group.
2+Increases  in  8-isoprostane  and  myocardial  Ca concentrations  were  signiﬁcantly  inhibited  in both  hANP
groups.
Conclusions:  This  study  demonstrated  that  hANP  ameliorates  ischemic  reperfusion  injury,  improves  post-
operative  myocardial  contractility,  and  reduces  reperfusion  arrhythmias.  We  suggest  that  hANP  allows
aortic  cross-clamping  to be prolonged  and  thereby  exerts  a direct  myocardial  protective  effect  against
iac  s
2  Japcardiac  arrest  during  card
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Human atrial natriuretic peptide (hANP; carperitide, Suntory
nc., Osaka, Japan, and Daiichi Sankyo Co., Ltd., Tokyo, Japan)
xerts various pharmacological actions including natriuretic and
asodilatory activities, as well as myocardial protection [1–3].
ANP has currently been used to treat patients with heart failure
y natriuretic actions, vasodilatory actions, and inhibition of the
enin-angiotensin system [3,4]. Several studies have demonstrated
eneﬁcial effects of hANP on experimentally induced ischemic
eperfusion myocardial injury [5,6]. Kuga et al. reported that
ANP administration, combined with percutaneous coronary inter-
ention, suppressed reperfusion phenomena and preserved left
entricular function through improvement of regional wall motion
6].  An inhibitory effect on left ventricular remodeling, reduced left
∗ Corresponding author at: The Department of Cardiovascular Surgery, Nihon
niversity School of Medicine, 30-1 Oyaguchi-kamimachi, Itabashi-ku, Tokyo, 173-
610, Japan. Tel.: +81 3 3972 8111; fax: +81 3 3955 9818.
E-mail address: shunji86@hotmail.com (S. Osaka).
914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
oi:10.1016/j.jjcc.2012.02.006urgery.
anese  College  of Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
ventricular arrhythmias, and ejection fraction maintenance after
ischemic reperfusion have also been demonstrated [5–7]. Kitakaze
et al. reported a randomized trial (J-WIND) in which hANP was
administered as an adjunct to reperfusion treatment for acute
myocardial infarction [8].  They showed that adjunctive, acute-
phase treatment with hANP after reperfusion therapy in patients
with acute myocardial infarction reduced infarct size and increased
the left ventricular ejection fraction during the chronic phase. hANP
has also been demonstrated to suppress the renin-aldosterone
system, decrease sympathetic nervous system activity, and dilate
coronary arteries [3]. In addition, hANP has been proposed to inhibit
endothelin-1, inﬂammatory cytokines, and tumor necrosis factor-
, as well as reducing oxygen radical cell damage and calcium
overload after ischemic reperfusion [9,10].
We have suggested the efﬁcacy of low dose continuous infu-
sion of hANP during cardiopulmonary bypass (CPB) during cardiac
surgery [11,12].  It has been recognized that hANP decreases devel-
opment of arrhythmias during unstable conditions after cardiac
surgery. An inhibitory effect on left ventricular remodeling and
reduced ischemic reperfusion injury have been reported by admin-
istering an intravenous infusion of hANP during cardiac surgery
vier Ltd. All rights reserved.
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Fig. 1. Experimental method and groups. Thirty-two pigs were divided into 4
groups; 15 min  clamping (control 15 min group n = 8), hANP 15 min  clamping (hANP
15  min  group n = 8), 30 min clamping (control 30 min  group n = 8) and hANP 30 minS. Osaka et al. / Journal o
13,14]. Therefore, we anticipated that hANP would be efﬁcacious
n achieving intraoperative myocardial protection. Our previous
tudy has already demonstrated that intracoronary administration
f hANP 100 g to pig hearts as an adjuvant to cardioplegia reduced
schemic reperfusion injury [15,16].
The effect on left ventricular function and arrhythmias after
schemic reperfusion injury were not thoroughly investigated in
he previous study. Therefore, we evaluated the left ventricular
unction by Emax and Tau, and then we measured the number
f premature ventricular contractions (PVCs) after reperfusion in
he present study. Furthermore, the present study aimed to reveal
hether hANP allows the aortic cross-clamp time to be prolonged.
e investigated whether hANP alone inhibits myocardial ischemic
eperfusion injury without cardioplegia during cardiac arrest.
aterials and methods
xperiment preparation
Thirty-two male pigs (41 ± 2.2 kg) were used for the exper-
ments. An intramuscular injection of pentobarbital sodium
20 mg/kg) was administered as premedication and anesthesia
as maintained with continuous intravenous infusion of ketamine
ydrochloride (1 mg/kg/h). After tracheal intubation, controlled
echanical ventilation was established at 20–25 breaths/min with
 tidal volume of 10–15 mL/kg by means of volume-controlled ven-
ilation (Servo 900-E, Siemens-Elema Inc., Stockholm, Sweden).
imb lead electrocardiograms were employed for monitoring the
onditions of the animals. A venous line was  inserted into the
ight internal jugular vein for injection. The left femoral artery was
annulated to monitor continuous aortic pressure. A catheter (CX-
54U, Cathex Co., Ltd., Tokyo, Japan) was placed in the coronary
inus via the left internal jugular vein for blood collection. The tho-
ax was opened in the supine position via median sternotomy, after
ystemic heparinization (300 U/kg). A dual-stage venous cannula
TF-024-L, Research Medical Inc., Midvale, Utah, USA) was  placed
n the right atrium, and an aortic cannula (Medtronic Inc., Min-
eapolis, MN,  USA) was inserted into the ascending aorta. A gyro
ump (Kyocera Corp., Kyoto, Japan) and an oxygenator [HPO-20-
C, Senko IKEA Kogyo (Mara), Tokyo, Japan] were prepared for
PB. A vent tube was inserted through the left atrium into the left
entricle.
All animals received humane care in compliance with the Prin-
iples of Laboratory Animal Care and the Guide for the Care and Use
f Laboratory Animals (www.nap.edu/catalog/5140.html).
xperimental groups
ardiac surgery models
Thirty-two pigs were placed on CPB with mild hypothermia
t 27 ◦C, and 5 min  thereafter aortic cross-clamping was per-
ormed with electrically induced ventricular ﬁbrillation. During
ortic cross-clamping, the blood was re-warmed to 32 ◦C. This
ethod approximates the intermittent aortic cross-clamping (IAC)
hich is one of the protective procedures applied during coronary
rtery bypass grafting (CABG) [17]. We  use IAC for CABG in our
nstitute. Experimental pigs were divided into 4 groups: 15 min
lamping (control 15 min  group, n = 8); hANP 15 min  clamping
hANP15 min  group, n = 8); 30 min  clamping (control 30 min  group,
 = 8); and hANP 30 min  clamping (hANP 30 min  group, n = 8). A
00 g (20 g/mL 5 mL)  dose of hANP was administered via the
orta near the aortic clamper using a 27 G needle immediately
fter clamping. Then, the aorta was ﬂushed with 10 mL  of normal
aline in hANP groups. The control groups received 15 mL  ﬂushes
ith normal saline. At 20 min  after declamping, the animals wereclamping (hANP 30 min group n = 8). A 100 g dose of hANP (20 g/mL 5 mL) was
administered via the aorta after clamping. Cont, control; Ns, normal saline; hANP,
human atrial natriuretic peptide; CPB, cardiopulmonary bypass.
weaned from CPB (Fig. 1). No inotropic drugs were administered
during the study. Fresh tissue was taken from the inner layer of
the left ventricular free wall after completion of the experimental
protocol.
Biochemical parameters
Plasma cyclic guanosine monophosphate (c-GMP) and 8-
isoprostane (prostaglandin F2)  were measured in samples
collected from the coronary sinus at 3 time points: before aor-
tic clamping, immediately after declamping, and 30 min  after
declamping. cGMP concentration was  measured using YAMASA
Cyclic GMP  Assay Kit (Yamasa Corp., Chiba, Japan) and 8-
isoprostane was measured using Cayman Chemical Company
8-isoprostane EIA kit (Cayman Chemical Company, Ann Arbor, MI,
USA).
For determination of myocardial Ca2+ and residual adenosine
triphosphate (ATP) levels, myocardial specimens were snap-frozen
immediately after the completion of experimental protocol by cut-
ting off the muscle around the diagonal branch; the myocardium
was isolated from inside of the inner membrane. For evaluation
of ischemia-reperfusion injury, we collected baseline data before
CPB (N = 8). A portion of each specimen was immediately frozen
with liquid nitrogen. After 0.1 N hydrochloric acid cooled in ice
was added to the frozen specimen, the myocardial specimen was
homogenized. The homogenate was  centrifuged at 13,000 rpm and
4 ◦C for 40 min. The Ca2+ concentration was  measured by atomic
absorption spectrophotometry using a Hitachi Z 6100 analyzer
(Hitachi, Ltd., Tokyo, Japan). ATP was measured by the ﬁreﬂy
luciferin-luciferase method using a Kikkoman ATP assay kit (Kikko-
man, Ltd., Tokyo, Japan).
Hemodynamic measurements
A conductance catheter tip manometer (2012-6-27-P, Alpha
Medical Instruments Inc., Madero, California, USA) was  inserted
through the aortic valve into the left ventricle from the left carotid
artery. A catheter tip manometer (811-195S/ANP534, Sentron Inc.,
Zoetermeer, Netherlands) was  also inserted into the left ventricle
to monitor continuous left ventricular pressure. The left ventricu-
lar pressure volume loop (P–V loop) was recorded using a Sigma-5
(Cardio Dynamics Inc., Zoetermeer, Netherlands).
Hemodynamic data, i.e. aortic pressure, Emax, which is a sen-
sitive myocardial contractile force indicator, and Tau, which is a
sensitive measure of myocardial diastolic function, were calculated
68 S. Osaka et al. / Journal of Card
Fig. 2. Nuclear chromatin was classiﬁed according to light microscopic ﬁndings.
Nuclear chromatin was  observed in myocardial cells under light microscopy and
classiﬁed according to four grades [normal (−), mild ischemic changes (+), severe
ischemic changes (++), and irreversible ischemic changes (+++)]. (−) No aggrega-
tion of chromatin, round nuclear bodies, and homogenously stained nuclei. (+) Mild
aggregation of chromatin, and relatively homogenously stained nuclei. (++) High
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gggregation of chromatin, but presence of stained nuclei. (+++) High aggregation of
hromatin, and absence of stained nuclei.
y analyzing the P–V loop with Conduct PC (Cardio Dynamics Inc.).
e compared Emax before CPB with that after CPB to evaluate con-
ractile function. We  then compared Tau before CPB with that after
PB to evaluate diastolic function. Moreover, to assess reperfusion
rrhythmias, PVCs were counted during the 30 min  period after
eperfusion.
istopathological studies
Another portion of myocardial specimens was examined micro-
copically. For microscopy, muscle specimens were ﬁxed with a
.5% glutaraldehyde ﬁxative at 4 ◦C for 12 h. The specimens were
ehydrated in ethanol and then propylene oxide, and embedded
n Quetol 812 (Nissin EM Co., Ltd., Tokyo, Japan). The embedded
pecimens were sectioned using an Ultracut UCT ultramicrotome
Leica Microsystems, Vienna, Austria) to prepare semi-ultrathin
ections and ultrathin sections. The semi-ultrathin sections were
tained with toluidine blue, and observed using a light microscope
o examine nuclear chromatin in myocardial cells. Nuclear chro-
atin was classiﬁed according to four grades (normal, mild, severe,
rreversible) as in a previous study [15] to assess ischemic changes
uantitatively in each treatment group (Fig. 2). We  examined 400
andomly selected nuclei. The ultrathin sections were double-
tained with uranyl acetate and lead citrate, and observed using
n electron microscope JEM 1200EX (JEOL Ltd., Tokyo, Japan). All
icroscopic examinations were performed by blinded observers.
ig. 3. Plasma concentrations of cGMP and 8-isoprostane. After reperfusion, plasma cGM
5  min  group, p = 0.005; control 30 min  group vs. hANP 30 min  group, p < 0.001). Infusion o
0  min arrest group (control 30 min  group vs. hANP 30 min  group, p = 0.008) and 30 min a
roup, p = 0.049; control 30 min  group vs. hANP 30 min group p = 0.020). c-GMP, cyclic guiology 60 (2012) 66–71
Statistical analysis
All data are expressed as means ± standard deviation. The paired
t-test and one factor analysis of variance were applied to test the
statistical signiﬁcance of differences in each group. Signiﬁcant dif-
ferences among the groups, if observed, were analyzed by the
Scheffe method of multiple comparison, and p < 0.05 was consid-
ered signiﬁcant.
Results
Hemodynamics
There were no signiﬁcant differences in mean aortic pres-
sure among the 4 groups: “pre CPB and post CPB” values were
78.4 ± 7.7 mmHg  and 75 ± 7.6 mmHg for the control 15 min  group,
79.2 ± 5.4 mmHg  and 72.8 ± 4.8 mmHg  for the hANP 15 min  group,
80 ± 5.4 mmHg  and 73 ± 6.4 mmHg  for the control 30 min  group,
and 81.5 ± 4.4 and 76 ± 5.5 mmHg  for the hANP 30 min group,
respectively.
Plasma concentration of cGMP
The changes in plasma cGMP concentrations in each group are
shown in Fig. 3A. After reperfusion, plasma cGMP levels were sig-
niﬁcantly increased in the hANP groups (control 15 min  group
41.2 ± 11.0 pmol/mL vs. hANP 15 min  group 106.5 ± 11.0 pmol/mL,
p = 0.005; control 30 min  group 36.7 ± 5.5 pmol/mL vs. hANP 30 min
group 127.2 ± 19.1 pmol/mL, p < 0.001).
Plasma concentration of 8-isoprostane
The changes in plasma 8-isoprostane concentrations in each
group are shown in Fig. 3B. Infusion of hANP signiﬁcantly inhibited
the increase in 8-isoprostane after declamping in the 30 min  arrest
group (control 30 min  group 111.6 ± 13.4 vs. hANP 30 min  group
53.4 ± 7.6, p = 0.008) and concentrations were elevated 30 min after
declamping in both arrest groups (control 15 min  group 102.2 ± 9.8
vs. hANP 15 min group 55.1 ± 6.5, p = 0.049; control 30 min  group
118.6 ± 19.8 vs. hANP 30 min  group 56.8 ± 10.1 p = 0.020).Myocardial Ca2+ levels are shown in Fig. 4A. Infusion
of hANP signiﬁcantly inhibited the increase in myocardial
P was signiﬁcantly increased in the hANP groups (control 15 min  group vs. hANP
f hANP signiﬁcantly inhibited the increase in 8-isoprostane after declamping in the
fter declamping in each of the arrest groups (control 15 min  group vs. hANP 15 min
anosine monophosphate; Cont, control; hANP, human atrial natriuretic peptide.
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Fig. 4. Tissue concentrations of Ca2+ and residual ATP. After reperfusion, myocardial Ca2+ was signiﬁcantly increased in the control groups (pre vs. control 15 min  group,
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p = 0.015; pre vs. control 30 min  group, p = 0.035). The myocardial Ca2+ levels in co
5  min  group, p = 0.002; control 30 min  group vs. hANP 30 min  group, p = 0.110). Aft
ontrol  30 min  group (vs. pre, p = 0.001; vs. control 15 min  group, p = 0.022; vs. hAN
a2+ after reperfusion. The baseline myocardial Ca2+ level
as 0.034 ± 0.002 mg/wet g prior to CPB. After reperfusion,
yocardial Ca2+ concentrations were signiﬁcantly increased
n control groups (pre vs. control 15 min  group, p = 0.015;
re vs. control 30 min  group, p = 0.035). Myocardial Ca2+ lev-
ls in control groups were lower than those in the hANP
roups (control 15 min  group 0.066 ± 0.0074 mg/wet g vs.
ANP 15 min  group 0.043 ± 0.0044 mg/wet g, p = 0.002; con-
rol 30 min  group 0.063 ± 0.0032 mg/wet g vs. hANP 30 min  group
.051 ± 0.0043 mg/wet g, p = 0.110).
issue concentrations of residual ATP
The residual ATP levels in the myocardium are shown
n Fig. 4B. After reperfusion, residual ATP levels in the
yocardium were signiﬁcantly decreased in the control 30 min
roup (pre CPB as baseline 112.9 ± 15.3 mol/L, p = 0.001; con-
rol 15 min  group 83.2 ± 7.9 mol/L, p = 0.022; control 30 min
roup 35.0 ± 9.4 mol/L, hANP 30 min  group 83.3 ± 10.2 mol/L,
 = 0.015). Infusion of hANP signiﬁcantly inhibited the decrease in
he ATP level after reperfusion in the 30 min  arrest group.ardiac catheterization
ecovery of Emax
Emax values, representing myocardial contractile force, are
hown in Fig. 5A. After reperfusion, Emax was signiﬁcantly
ig. 5. Recovery of Emax and reperfusion arrhythmias. After reperfusion, Emax was  signiﬁc
rrhythmias, numbers of PVCs were signiﬁcantly lower in the hANP groups than in the co
roup  than in the control 30 min  group (control 15 min  group vs. hANP 15 min  group, p = 0
s.  control 30 min  group, p = 0.040). PVC, premature ventricular contraction; ESPVR, end-s
eptide.roups were lower than those in the hANP groups (control 15 min group vs. hANP
erfusion, residual ATP levels in the myocardium were signiﬁcantly decreased in the
in  group, p = 0.015). Cont, control; hANP, human atrial natriuretic peptide.
decreased in the control 30 min  group. Infusion of hANP signiﬁ-
cantly inhibited the decrease on Emax recovery after reperfusion
in the 30 min  arrest group (control 15 min  group: pre 5.56 ± 0.17,
post 3.9 ± 0.11, recovery of Emax (%) 70.17 ± 1.07% vs. hANP
15 min  group: pre 5.74 ± 0.40, post 5.15 ± 0.50, recovery of
Emax 89.24 ± 4.34%, control 30 min  group: pre 4.57 ± 0.19, post
2.95 ± 0.24 (vs. pre p = 0.049), recovery of Emax 64.50 ± 4.84%, hANP
30 min  group: pre 4.15 ± 0.30, post 4.73 ± 0.31 (vs. pre p > 0.05),
recovery of Emax 115.05 ± 9.89%).
Changes in Tau
Tau, as a parameter of diastolic function, did not differ signiﬁ-
cantly among the groups (control 15 min  group: pre 27.81 ± 0.80,
post 31.46 ± 1.26, change in Tau (%) 113.3 ± 4.62% vs. hANP
15 min  group: pre 27.92 ± 1.02, post 26.90 ± 1.98, change in
Tau 96.5 ± 6.86%, control 30 min  group: pre 33.33 ± 1.77, post
37.43 ± 1.37, change in Tau 112.6 ± 2.6%, hANP 30 min group:
34.75 ± 2.66, post 35.92 ± 4.82, change in Tau 102 ± 7.4%).
Reperfusion arrhythmias
PVCs
The number of PVCs, serving as an index of reperfusion arrhyth-
mias are shown in Fig. 5B. Infusion of hANP signiﬁcantly inhibited
increases in PVC after reperfusion as compared to numbers in
the control groups (control 15 min  group 34.8 ± 1.8 count/30 min
antly decreased in the control 30 min group (vs. pre p = 0.049). Among reperfusion
ntrol groups, and the PVC count was also signiﬁcantly lower in the control 15 min
.033; control 30 min  group vs. hANP 30 min group, p = 0.002; control 15 min group
ystolic pressure–volume relationship; Cont, control; hANP, human atrial natriuretic
70 S. Osaka et al. / Journal of Card
Fig. 6. Histopathological studies, ischemic changes in nuclear chromatin. There
were no signiﬁcant differences among the 15 min  arrest groups. Severe ischemic
changes were increased in the control 30 min  group but changes in the hANP 30 min
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cnd 15 min  groups were quite similar. There were slight but irreversible ischemic
hanges in the control 30 min  group. Cont, control; hANP, human atrial natriuretic
eptide.
s. hANP 15 min  group 14.8 ± 2.5 count/30 min p = 0.033, con-
rol 30 min  group 53.3 ± 5.8 count/30 min  vs. hANP 30 min  group
4.6 ± 5.3 count/30 min  p = 0.002).
istopathological studies
schemic changes in nuclear chromatin
We used light microscopy with Toluidine Blue-staines images
o examine ischemic changes in nuclear chromatin, which were
lassiﬁed according to four grades as in a previous study (Fig. 2)
15].
There were no signiﬁcant differences between the 15 min arrest
roups. The 15 min  arrest groups showed mild ischemic changes
ut it was not irreversible. The incidence of severe ischemic changes
as 1.3% (5/400) in the control 15 min  group and 2.0% (8/400) in the
ANP 15 min  group. The incidence of severe ischemic changes was
5.5% (62/400) in the control 30 min  group and 3.5% (14/400) in
he hANP 30 min  group. There were irreversible ischemic changes
n the control 30 min  group, affecting 4% of cells (16/400). Injection
f hANP signiﬁcantly inhibited ischemic change in the 30 min  arrest
roup (Fig. 6).
lectron microscopic images
We  evaluated the light microscopic results in greater detail, by
mploying electron microscopy. There were few severe ischemic
hanges in the 15 min  arrest groups, as evidenced by normal
itochondria, myocardial ﬁbers, and myocardial nuclei. Severe
schemic changes and irreversible ischemic changes were increased
n the control 30 min  group, as shown by swollen mitochondria,
yocardial ﬁbers with fuzzy contraction bands, and aggregation
f chromatin around the nuclei. There were few severe ischemic
hanges in the hANP 30 min  group, with mitochondria, myocar-
ial ﬁbers, and myocardial nuclei appearing essentially normal
n electron microscopic images. Electron microscopy revealed a
emarkable difference between the control 30 min group and the
ANP 30 min  groups.
iscussion
It is generally accepted that a single brief occlusion of a coro-
ary artery (5–15 min) does not damage the myocardium in terms
f necrosis or persisting contractile abnormalities. However, a
ingle brief arrest might induce reversible injury, i.e. myocardial
schemic reperfusion injury manifesting as reperfusion arrhyth-
ias, microvascular damage, myocardial stunning, or ‘reversible
echanical dysfunction’, myocardial remodeling, and the trig-
ering of apoptosis [18,19]. Prolonged myocardial ischemia can
ause irreversible myocardial injury. The mechanisms of ischemiciology 60 (2012) 66–71
reperfusion injury are thought to involve more than 26 pathways
including oxidative stress, Ca2+-overload, decreasing residual ATP
levels, inﬂammatory cytokines, neutrophils, endothelin, and so on.
These various pathways may  function either together or separately
[20–23]. There are two main hypotheses, oxidative stress and Ca2+-
overload, which have been proposed to explain the pathogenesis of
ischemic reperfusion injury. These two mechanisms are most likely
inter-related but whether they operate simultaneously or, instead,
one precedes the other is not known.
In our previous study, we  demonstrated that hANP improves
ischemic reperfusion injury and suggested that hANP exerts direct
myocardial protective effects against myocardial ischemic reperfu-
sion injury associated with using cardioplegia during CPB [15,16].
We did not evaluate the effect on left ventricular function and
arrhythmias after ischemic reperfusion injury in the previous study.
Possible beneﬁcial effects of hANP on ischemic reperfusion injury
The present study showed histopathologically that the con-
trol 15 min  arrest group developed reversible myocardial injury
(slight ischemic change). The control 30 min  arrest group began to
show severe ischemic changes as irreversible myocardial injury in
histopathological studies. In this group, the prevalence of arrhyth-
mias after reperfusion increased and the myocardial contractility
after reperfusion (Emax) was  decreased.
In the present study, a “hANP shot”, i.e. intravenous adminis-
tration of hANP, signiﬁcantly inhibited reperfusion arrhythmias
with 15 min  arrest. With prolonged (30 min) arrest, administra-
tion of hANP inhibited ischemic reperfusion injury according to
histopathological studies, decreased reperfusion arrhythmias, and
improved myocardial contractility as reﬂected by Emax. These
ﬁndings suggested that hANP exerts a direct improved cardiac
contraction and reduced reperfusion arrhythmias after cardiac
arrest during CPB without cardioplegia. In other words, the hANP
shot allowed prolonged aortic cross-clamping time and inhibited
ischemic reperfusion injury associated with cardiac arrest without
cardioplegia.
We showed plasma concentrations of c-GMP to be increased
after hANP shot administration under ischemic conditions and that
myocardial Ca2+ concentrations were signiﬁcantly decreased after
reperfusion. Based on the results of the present study, we speculate
that hANP leads to the synthesis of cGMP and inhibits increases
in Ca2+ concentrations via activation of c-GMP-dependent protein
kinase (cGK), and Ca2+ is then released from cells.
Oxidative stress injures myocardial cell membranes and mito-
chondria [22]. In our present study, concentrations of 8-isoprostane
in plasma samples collected from the coronary sinus, a marker of
cardiac oxidative stress, were decreased after hANP shot adminis-
tration under ischemic conditions. Also mitochondria in electron
microscopy were preserved and ischemic changes in nuclear chro-
matin were inhibited by hANP shot. Oxidative stress may result
in cellular defects including depression of sarcolemmal (SL) Ca2+-
pump ATPase and Na+–K+ ATPase activities. Depression of the
Ca2+-regulatory mechanism by reactive oxygen species (ROS) ulti-
mately results in Ca2+ overload. On the other hand, an increase
in myocardial Ca2+ concentrations during ischemia induces the
conversion of xanthine dehydrogenase to xanthine oxidase and
subsequently results in the generation of superoxide radicals.
Kiemer et al. showed hANP to inhibit activation of iNOS through
nuclear factor-kappa B (NF-B) [24]. Kathrin et al. showed c-GMP
to inhibit NF-B and tumor necrosis factor- (TNF-) [25]. These
results suggest that hANP inhibits cardiac oxidative stress after
ischemic reperfusion through NF-B. Oxidative stress and Ca2+
overload seem to occur together. In this study, hANP maintained
myocardial residual ATP after ischemic reperfusion. Mitochondrial
injury after ischemic reperfusion reduces ATP synthetic capacity.
f Card
I
l
I
a
s
a
t
i
v
p
a
i
h
r
a
H
T
n
w
t
V
w
w
C
C
f
a
g
s
a
p
c
A
t
C
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[S. Osaka et al. / Journal o
t has been reported that an increase in the c-GMP concentration
eads to a decrease in oxygen consumption in the myocardium [26].
t is thus reasonable to speculate that inhibition of Ca2+ overload
nd oxidative stress with administration of hANP preserves ATP
ynthetic capacity.
hANP reportedly inhibits inﬂammatory cytokines such as TNF-
nd modulates neutrophil functions, as well as exerting protec-
ive effects against neutrophils inducing endothelial cytotoxicity
n ischemic reperfusion injury [27].
In other words, hANP may  be an ideal medication for the pre-
ention of ischemic reperfusion injury, which occurs via several
athways.
Administering hANP shot may  facilitate weaning from CPB and
void postoperative low out-put syndromes. Treatment with hANP
s anticipated to provide cardiac protection during prolonged open
eart surgery and cardiac transplantation. Based on the satisfactory
esults obtained in our present experiment, clinical application was
pproved by the Ethics Review Board of Nihon University Itabashi
ospital and a clinical trial of the “hANP shot” has already begun.
o date, satisfactory results have been obtained.
This study employed an acute phase model and thus we  could
ot assess chronic phase results. We  hypothesize that treatment
ith hANP in the acute phase during CPB might prove more effec-
ive in chronic phase treatment of postoperative heart failure.
In this study we evaluated “hANP shot” without cardioplegia.
arious methods for cardiac protection have been reported in the
orld. Therefore, we should evaluate the effect of and problems
ith “hANP shot” for cardiac protection in the future.
onclusions
The present study showed administration of hANP to inhibit
a2+ overload and oxidative stress associated with ischemic reper-
usion injury.
The hANP shot exerts a direct myocardial protective effect
gainst myocardial ischemic reperfusion injury without cardiople-
ia, inhibits severe ischemic change, as shown by histopathological
tudies, improves cardiac contraction, and reduces reperfusion
rrhythmias after cardiac arrest during CPB.
The hANP shot allows the aortic cross-clamping time to be
rolonged and inhibits so-called stunning of the myocardium asso-
iated with cardiac surgery.
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